Bristol-Myers Squibb (BMY) Tops Q1 EPS by 7c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bristol-Myers Squibb Co. (BMY) PT Lowered to $53 at Deutsche Bank
April 29, 2024 5:27 AM EDTDeutsche Bank analyst James Shin lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $53.00 (from $55.00) while maintaining a Hold rating.
The analyst comments "We get it - BMY's cost cut is poor optics given low visibility for late-decade revenues and... More
Bristol-Myers Squibb (BMY) stock slips despite earnings beat
April 25, 2024 7:09 AM EDT(Updated - April 25, 2024 7:26 AM EDT)
Bristol-Myers Squibb (NYSE: BMY) reported better-than-expected earnings and revenue for the first quarter of 2024.
Still, BMY stock fell by 1.7% in premarket trading.
The company reported a loss per share of $4.40, compared to the estimated loss per share of $4.47. Revenue for the quarter reached $11.9 billion, exceeding the consensus... More
